Symposium Of Vaccine Development To Highlight UCSF "World AIDS Day" Events

November 23, 1998

The UCSF AIDS Research Institute (ARI) is sponsoring a special symposium on vaccine development as part of "World AIDS Day" activities on Tuesday, December 1.

Titled "On the Road to an HIV Vaccine," the symposium is free and open to the public. The event is scheduled for 2:00-5:00 pm in Cole Hall, 513 Parnassus, on the UCSF campus. Interested persons should register by phone at 415-597-UCSF or by e-mail to ari@psg.ucsf.edu. A reception will follow for all those attending.

"Innovative, community-based frontline prevention efforts in the U.S. have greatly reduced the spread of HIV, but the infection continues to advance in other communities and nations. In the developing world, the disease continues unchecked, and a vaccine is likely to be the only hope for eradication to save the next generation," said Thomas J. Coates, PhD, director of the UCSF ARI.

The symposium program is designed "to reflect on the past, examine present challenges, and define a path for the future," he added.

Neal Nathanson, MD, the newly named director of the Office of AIDS Research of the National Institutes of Health, will lead off the event as keynote speaker. He will address the question, "Why is an AIDS vaccine so hard to develop?" Appointed to his current post in May of this year, Nathanson has made HIV vaccine development a high priority and increased the resources devoted to this effort. He has a long history of work in polio vaccines.

Lawrence K. Altman, MD, medical correspondent for The New York Times, will give a presentation on "Perspectives on the Challenges of the AIDS Vaccine." One of the few medical doctors working fulltime as a daily newspaper reporter, Altman has been with the Times since 1969 and is a former chief of the epidemiology and immunization program of the U.S. Department of Public Health.

Jay Levy, MD, UCSF professor of medicine and co-discoverer of HIV in 1983, will moderate a symposium panel discussion on "The Current State of the Vaccine." Under the auspices of the UCSF ARI, Levy has organized a campus-wide effort on vaccine research. Panelists will include UCSF faculty members Susan Buchbinder, MD; James O. Kahn, MD; Bernard Lo, MD; and Raul Andino-Pavlovsky, PhD.

The symposium will conclude with a preview showing of clips from a new video about young people living with HIV. Titled "It Could Be You," the video was produced by Jako/Guberman in collaboration with MTV, which will air it the evening of December 1.

The symposium is sponsored in part by Glaxo Wellcome, and the reception will be hosted by Chiron Corporation.

As part of the day's activities, UCSF and the Commonwealth Club of San Francisco will co-sponsor a luncheon program on "Hope for an AIDS Vaccine." The discussion will feature Nathanson and Altman, with moderator Margaret Chesney, PhD, UCSF professor of medicine and co-director of the UCSF Center for AIDS Prevention Studies. Open to the public, the event will take place at the Club, 595 Market Street in San Francisco. For information and reservations, call 415-597-6705.

Other events for "World AIDS Day" will include an observance at the National AIDS Memorial Grove in Golden Gate Park. Special guests at the program will include actress/activist Judith Light, writer Armistead Maupin, and UCSF ARI director Coates. The program is scheduled for 11:00 am to 1:00 pm at the Grove, across from the tennis courts at Bowling Green and Middle East Drive. The public is invited. For more information, call 415-263-0387.
-end-
Note to the media: Reporters are invited to cover all events. Please call Corinna Kaarlela in the UCSF/SFGHMC News Office at 415-476-3804. There will be a reserved section for media representatives at the symposium in Cole Hall.
-end-


University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.